Mazin, I.;                     Chernomordik, F.;                     Fefer, P.;                     Matetzky, S.;                     Beigel, R.    
        The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. J. Clin. Med. 2022, 11, 1904.
    https://doi.org/10.3390/jcm11071904
    AMA Style
    
                                Mazin I,                                 Chernomordik F,                                 Fefer P,                                 Matetzky S,                                 Beigel R.        
                The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. Journal of Clinical Medicine. 2022; 11(7):1904.
        https://doi.org/10.3390/jcm11071904
    
    Chicago/Turabian Style
    
                                Mazin, Israel,                                 Fernando Chernomordik,                                 Paul Fefer,                                 Shlomi Matetzky,                                 and Roy Beigel.        
                2022. "The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients" Journal of Clinical Medicine 11, no. 7: 1904.
        https://doi.org/10.3390/jcm11071904
    
    APA Style
    
                                Mazin, I.,                                 Chernomordik, F.,                                 Fefer, P.,                                 Matetzky, S.,                                 & Beigel, R.        
        
        (2022). The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. Journal of Clinical Medicine, 11(7), 1904.
        https://doi.org/10.3390/jcm11071904